Zachery Reichert
Associate Professor of Internal Medicine
Associate Professor of Urology
[email protected]

Available to mentor
Zachery Reichert
Clinical Associate Professor
  • Center Memberships
  • Recent Publications
    • Center Memberships
    • Center Member
      Rogel Cancer Center
    Recent Publications See All Publications
    • Journal Article
      Abstract CT222: Efficacy and safety of ceralasertib in the PLANETTE study in patients (pts) with ATM-altered advanced solid tumors (ASTs) or metastatic castration-resistant prostate cancer (mCRPC)
      Aggarwal R, Italiano A, Domchek S, Goodman O, Postel-Vinay S, Garcia-Donas J, Dorff T, Reichert Z, Cassier P, Shore N, Marshall C, Parr G, Irurzun-Arana I, Shah N, Lukashchuk N, Murina O, Slade D, Loembé B, Dean E, Sanai E, Abida W. Cancer Research, 2024 Apr 5; 84 (7_Supplement): ct222 - ct222. DOI:10.1158/1538-7445.am2024-ct222
    • Journal Article
      AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation.
      Apolo AB, Ballman KV, Sonpavde GP, Berg SA, Kim WY, Parikh RA, Teo MY, Sweis RF, Geynisman DM, Grivas P, Chatta GS, Reichert ZR, Kim JW, Bilen MA, McGregor BA, Srinivas S, Halabi S, Perez Burbano G, Morris MJ, Rosenberg JE. Journal of Clinical Oncology, 2024 Feb 1; 42 (4_suppl): lba531 - lba531. DOI:10.1200/jco.2024.42.4_suppl.lba531
    • Journal Article
      BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).
      Hussain MHA, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller CJ, Picus J, Reichert ZR, Szmulewitz RZ, Tagawa ST, Kuzel T, Bazzi L, Daignault-Newton S, Whang YE, Dreicer R, Stephenson RD, Rettig M, Shevrin D, Chinnaiyan A, Antonarakis ES. Journal of Clinical Oncology, 2024 Feb 1; 42 (4_suppl): 19 - 19. DOI:10.1200/jco.2024.42.4_suppl.19
    • Journal Article
      First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
      Rathkopf DE, Patel MR, Choudhury AD, Rasco DW, Lakhani NJ, Hawley JE, Aparicio A, Narayan V, Srinivas S, Runcie K, Emamekhoo H, Reichert ZR, Carducci MA, Wells AL, Liu C, Kandimalla R, Wu J, Nguyen MH, Pourdehnad M, Armstrong AJ. Journal of Clinical Oncology, 2024 Feb 1; 42 (4_suppl): 134 - 134. DOI:10.1200/jco.2024.42.4_suppl.134
    • Journal Article
      Muscadine grape skin extract in men with biochemically recurrent prostate cancer: A phase III, randomized, multicenter, placebo-controlled clinical trial.
      Mandl A, Zahurak M, Sfanos K, Metri N, Maughan BL, Taplin M-E, Shore ND, McKay RR, Reichert ZR, Szmulewitz RZ, Kessler ER, Heath EI, Dreicer R, Stein CA, Marshall CH, Markowski MC, Denmeade SR, Antonarakis ES, Carducci MA, Paller CJ. Journal of Clinical Oncology, 2024 Feb 1; 42 (4_suppl): 329 - 329. DOI:10.1200/jco.2024.42.4_suppl.329
    • Presentation
      Sequencing hormonal therapies after treatment intensification
      Reichert Z. 2024 Jan 25;
    • Journal Article
      Research autopsy programmes in oncology: shared experience from 14 centres across the world.
      Geukens T, Maetens M, Hooper JE, Oesterreich S, Lee AV, Miller L, Atkinson JM, Rosenzweig M, Puhalla S, Thorne H, Devereux L, Bowtell D, Loi S, Bacon ER, Ihle K, Song M, Rodriguez-Rodriguez L, Welm AL, Gauchay L, Murali R, Chanda P, Karacay A, Naceur-Lombardelli C, Bridger H, Swanton C, Jamal-Hanjani M, Kollath L, True L, Morrissey C, Chambers M, Chinnaiyan AM, Wilson A, Mehra R, Reichert Z, Carey LA, Perou CM, Kelly E, Maeda D, Goto A, Kulka J, Székely B, Szasz AM, Tőkés A-M, Van Den Bogaert W, Floris G, Desmedt C. J Pathol, 2024 Mar 29; DOI:10.1002/path.6271
      PMID: 38551513
    • Presentation
      Clinical trials- Annihilating the AR
      Reichert Z. 2023 Nov 28;